IMCC vs. MTEX, NAII, BGXX, ERNA, BGLC, CHRO, MTEM, GENE, PHXM, and BCDA
Should you be buying IM Cannabis stock or one of its competitors? The main competitors of IM Cannabis include Mannatech (MTEX), Natural Alternatives International (NAII), Bright Green (BGXX), Eterna Therapeutics (ERNA), BioNexus Gene Lab (BGLC), Chromocell Therapeutics (CHRO), Molecular Templates (MTEM), Genetic Technologies (GENE), PHAXIAM Therapeutics (PHXM), and BioCardia (BCDA). These companies are all part of the "medical" sector.
IM Cannabis (NASDAQ:IMCC) and Mannatech (NASDAQ:MTEX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, community ranking, risk, valuation and institutional ownership.
Mannatech received 276 more outperform votes than IM Cannabis when rated by MarketBeat users. Likewise, 74.80% of users gave Mannatech an outperform vote while only 42.86% of users gave IM Cannabis an outperform vote.
IM Cannabis has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500. Comparatively, Mannatech has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500.
Mannatech has higher revenue and earnings than IM Cannabis. Mannatech is trading at a lower price-to-earnings ratio than IM Cannabis, indicating that it is currently the more affordable of the two stocks.
7.7% of IM Cannabis shares are held by institutional investors. Comparatively, 13.0% of Mannatech shares are held by institutional investors. 41.5% of Mannatech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
In the previous week, IM Cannabis had 5 more articles in the media than Mannatech. MarketBeat recorded 7 mentions for IM Cannabis and 2 mentions for Mannatech. Mannatech's average media sentiment score of 0.93 beat IM Cannabis' score of 0.47 indicating that Mannatech is being referred to more favorably in the news media.
Mannatech has a net margin of -1.70% compared to IM Cannabis' net margin of -28.03%. Mannatech's return on equity of -19.19% beat IM Cannabis' return on equity.
Summary
Mannatech beats IM Cannabis on 11 of the 15 factors compared between the two stocks.
Get IM Cannabis News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMCC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
IM Cannabis Competitors List
Related Companies and Tools
